Who We Are
Alectos Therapeutics uncovers groundbreaking treatments that target the root biology of neurodegenerative and acute neurological disorders. The company focuses on identifying and developing innovative approaches to tackle complex conditions such as Alzheimer’s disease, Parkinson’s disease, and acute ischemic stroke.
Alectos’ pipeline is dedicated to developing new therapies for patients affected by these disorders. Our GBA2 program offers a disease-modifying approach aimed at correcting lysosomal dysfunction in neurodegenerative diseases like Parkinson’s disease and Batten disease. Our OGA program presents a neuroprotective strategy designed to counteract cellular stress in the brain. We initially partnered with Merck to pioneer the first clinical OGA inhibitor, but have since repatriated the program. Leveraging our extensive expertise and intellectual property, we are advancing novel OGA inhibitors as potential treatments for Alzheimer’s disease, Parkinson’s disease, acute ischemic stroke, and traumatic brain injury. We welcome partnership inquiries regarding our OGA and GBA2 programs and our advanced preclinical development candidates.
Development of novel agents as disease-modifying therapies for
neurological diseases
News
O-GlcNAcylation: a pro-survival response to acute stress in the cardiovascular and central nervous systems
O-GlcNAcylation is a unique monosaccharide modification that is ubiquitously present in numerous nucleoplasmic and mitochondrial proteins. The hexosamine biosynthesis pathway (HBP), which is a key branch of glycolysis, provides the unique sugar donor UDP-GlcNAc for the O-GlcNAc modification. Thus, HBP/O-GlcNAcylation can act as a nutrient sensor to perceive changes in nutrient levels and trigger O-GlcNAc modifications of functional proteins in cellular (patho-)physiology, thereby regulating diverse metabolic processes. An imbalance in [...]
O-GlcNAcylation and Its Roles in Neurodegenerative Diseases
As a non-classical post-translational modification, O-linked β-N-acetylglucosamine (O-GlcNAc) modification (O-GlcNAcylation) is widely found in human organ systems, particularly in our brains, and is indispensable for healthy cell biology. With the increasing age of the global population, the incidence of neurodegenerative diseases is increasing, too. The common characteristic of these disorders is the aggregation of abnormal proteins in the brain. Current research has found that O-GlcNAcylation dysregulation is involved in misfolding [...]
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s Disease Alectos to receive a $15 million upfront payment and is eligible to receive potential future development and commercial milestone payments Cambridge, Mass. and Burnaby, British Columbia – June 6, 2022 – Biogen Inc. (Nasdaq: BIIB) – Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and [...]